Expression pattern and prognostic significance of baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5) in breast cancer: A comprehensive analysis

Mehraj, Umar; Aisha, Shariqa; Sofi, Shazia; Mir, Manzoor Ahmad

doi:10.1016/j.adcanc.2022.100037

Cited by 53 publications

(14 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results were validated both in silico and in vitro . CDK2 is upregulated in breast tumors, and its vital role in cell cycle regulation makes CDK2 an attractive therapeutic target ( Sofi et al, 2022a ; Mehraj et al, 2022e ; Mehraj et al, 2022f ). Together, these results demonstrate that ADA has high potential in reducing tumor growth and colonization of TNBC cells.…”

Section: Discussionmentioning

confidence: 99%

Adapalene inhibits the growth of triple-negative breast cancer cells by S-phase arrest and potentiates the antitumor efficacy of GDC-0941

et al. 2022

Self Cite

View full text Add to dashboard Cite

Although advances in diagnostics and therapeutics have prolonged the survival of triple-negative breast cancer (TNBC) patients, metastasis, therapeutic resistance, and lack of targeted therapies remain the foremost hurdle in the effective management of TNBC. Thus, evaluation of new therapeutic agents and their efficacy in combination therapy is urgently needed. The third-generation retinoid adapalene (ADA) has potent antitumor activity, and using ADA in combination with existing therapeutic regimens may improve the effectiveness and minimize the toxicities and drug resistance. The current study aimed to assess the anticancer efficacy of adapalene as a combination regimen with the PI3K inhibitor (GDC-0941) in TNBC in vitro models. The Chou–Talalay’s method evaluated the pharmacodynamic interactions (synergism, antagonism, or additivity) of binary drug combinations. Flow cytometry, Western blotting, and in silico studies were used to analyze the mechanism of GDC–ADA synergistic interactions in TNBC cells. The combination of GDC and ADA demonstrated a synergistic effect in inhibiting proliferation, migration, and colony formation of tumor cells. Accumulation of reactive oxygen species upon co-treatment with GDC and ADA promoted apoptosis and enhanced sensitivity to GDC in TNBC cells. The findings indicate that ADA is a promising therapeutic agent in treating advanced BC tumors and enhance sensitivity to GDC in inhibiting tumor growth in TNBC models while reducing therapeutic resistance.

show abstract

Section: Discussionmentioning

confidence: 99%

Adapalene inhibits the growth of triple-negative breast cancer cells by S-phase arrest and potentiates the antitumor efficacy of GDC-0941

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…During the premalignant stage, apoptosis, proliferation, and cell cycle regulatory markers differ significantly. Apoptosis is enhanced in both ductal carcinomas in situ and invasive breast cancers [ 101 ]. Invasive breast cancer apoptosis appears lower than proliferation in normal breast epithelium [ 27 , 99 ].…”

Section: Suppose Pathwaymentioning

confidence: 99%

Function and Application of Flavonoids in the Breast Cancer

Park

Kim

et al. 2022

IJMS

View full text Add to dashboard Cite

Breast cancer is one of the top causes of death, particularly among women, and it affects many women. Cancer can also be caused by various factors, including acquiring genetic alteration. Doctors use radiation to detect and treat breast cancer. As a result, breast cancer becomes radiation-resistant, necessitating a new strategy for its treatment. The approach discovered by the researchers is a flavonoid, which is being researched to see if it might help treat radiation-resistant breast cancer more safely than an approved medicine already being used in the field. As a result, this study focuses on the role of flavonoids in breast cancer suppression, breast cancer gene anomalies, and the resulting apoptotic mechanism.

show abstract

“…All the pdbqt files and contig files (which stored all the information regarding virtual screening) were kept in a directory for the virtual screening process. 32,33 The target receptor (prepared) was subjected to docking in contrast to the already prepared compound library using Autodock vina 4.0 (https:// vina.scripps.edu/), and a Perl script was employed for multiple ligands molecular docking. In each docking experiment, 10 separate runs were carried out, and every pose was selected based on docking score and binding energies.…”

Section: Molecular Docking Studiesmentioning

confidence: 99%

Computational Studies to Identify Potential Inhibitors Targeting the DprE1 Protein in Mycobacterium tuberculosis

Sheikh

Rizvi

et al. 2022

Int J. Pharm. Investigation

View full text Add to dashboard Cite

Background: DprE1, which is a flavoenzyme, is very important for cell wall biosynthesis in Mycobacterium tuberculosis (Mtb) and for the pathogenesis, virulence, lethality, and stress resistance of the host. Drug-resistant tuberculosis is a challenging global human health issue, necessitating the development of novel, more effective treatment regimens without adverse effects. DprE1 represents a potential therapeutic target. It was explored as a drug target utilizing benzothiazoles (BTZ), which are enormously potential anti-bacterial agents and are currently being explored as anti-mycobacterial entities. Materials and Methods: We used virtual screening of bioactive molecules from PubChem and ZINC databases targeting DprE1, having bioactive thousands of molecules known for anti-microbial activity. In the present study, we selected 100 compounds as the most promising candidates to act as potential DprE1 inhibitors to control this emerging condition of tuberculosis infection. To identify the six topranked compounds, molecular docking was used to calculate the binding affinities (ranging from -8.3 to 10.0 kcal/mol) between various compounds (C1-C6) and the DprE1 protein.Results: Based on the results of an ADMET analysis, these six chemicals are safer potential drug candidates, as neither AMES toxicity nor carcinogenicity is present when toxicological properties are considered. Out of 6 compounds, the top-ranked compound exhibiting the best binding affinity against the drug target DprE1 (Pdb-id;4FEH) receptor was further subjected to molecular dynamic simulation for 100 nanoseconds to check the stability and trajectories by root-mean-square deviation (RMSD) and root-mean-square fluctuation (RMSF) graphs and interacting coordinates using Desmond Schrodinger Software. Conclusion: Our in-silico investigation identified potent inhibitors for the DprE1 protein of Mtb, and these compounds can be considered and recommended as the lead molecules in the treatment of tuberculosis.

show abstract

Expression pattern and prognostic significance of baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5) in breast cancer: A comprehensive analysis

Cited by 53 publications

References 45 publications

Adapalene inhibits the growth of triple-negative breast cancer cells by S-phase arrest and potentiates the antitumor efficacy of GDC-0941

Adapalene inhibits the growth of triple-negative breast cancer cells by S-phase arrest and potentiates the antitumor efficacy of GDC-0941

Function and Application of Flavonoids in the Breast Cancer

Computational Studies to Identify Potential Inhibitors Targeting the DprE1 Protein in Mycobacterium tuberculosis

Contact Info

Product

Resources

About